Cargando…

Upregulation of CYP2S1 by oxaliplatin is associated with p53 status in colorectal cancer cell lines

Oxaliplatin displays a wide spectrum of antitumor activities and is widely used in the treatment of metastatic colorectal cancer (CRC). However, tumor responses to this agent are variable, and the underlying mechanisms are poorly understood. In the present study, oxaliplatin was found to strongly in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Chao, Zhou, Qian, Li, Minle, Tong, Xuemei, Sun, Jiayi, Qing, Yin, Sun, Liya, Yang, Xuhan, Hu, Xiaowen, Jiang, Jie, Yan, Xiaomei, He, Lin, Wan, Chunling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5016804/ https://www.ncbi.nlm.nih.gov/pubmed/27609465 http://dx.doi.org/10.1038/srep33078

Ejemplares similares

Common housekeeping proteins are upregulated in colorectal adenocarcinoma and hepatocellular carcinoma, making the total protein a better "housekeeper"
por: Hu, Xiaowen, et al.
Publicado: (2016)

Dysregulated 14-3-3 Family in Peripheral Blood Leukocytes of Patients with Schizophrenia
por: Qing, Ying, et al.
Publicado: (2016)

Analysis of the concentrations and size distributions of cell-free DNA in schizophrenia using fluorescence correlation spectroscopy
por: Jiang, Jie, et al.
Publicado: (2018)

Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer
por: Baba, H, et al.
Publicado: (2012)

KIF11 is upregulated in colorectal cancer and silencing of it impairs tumor growth and sensitizes colorectal cancer cells to oxaliplatin via p53/GSK3β signaling
por: Zhou, Yan, et al.
Publicado: (2021)

Salivary microbiome profiling reveals a dysbiotic schizophrenia-associated microbiota
por: Qing, Ying, et al.
Publicado: (2021)

Identification of the Niacin-Blunted Subgroup of Schizophrenia Patients from Mood Disorders and Healthy Individuals in Chinese Population
por: Sun, Liya, et al.
Publicado: (2018)

Scutellarin resensitizes oxaliplatin-resistant colorectal cancer cells to oxaliplatin treatment through inhibition of PKM2
por: Sun, Wei, et al.
Publicado: (2021)

Dysregulation of phospholipase and cyclooxygenase expression is involved in Schizophrenia
por: Yang, Xuhan, et al.
Publicado: (2021)

P53‑microRNA interactions regulate the response of colorectal tumor cells to oxaliplatin under normoxic and hypoxic conditions
por: Zhang, Jiayu, et al.
Publicado: (2023)

LINC00460-miR-149-5p/miR-150-5p-Mutant p53 Feedback Loop Promotes Oxaliplatin Resistance in Colorectal Cancer
por: Meng, Xiangfeng, et al.
Publicado: (2020)

Plasma Exosomal miRNA Expression Profile as Oxaliplatin-Based Chemoresistant Biomarkers in Colorectal Adenocarcinoma
por: Han, Jiayi, et al.
Publicado: (2020)

CYP2A6 Polymorphisms Associate with Outcomes of S-1 Plus Oxaliplatin Chemotherapy in Chinese Gastric Cancer Patients
por: Yang, Lin, et al.
Publicado: (2017)

Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer
por: Braun, M S, et al.
Publicado: (2003)

The AKT/GSK3β-Mediated Slug Expression Contributes to Oxaliplatin Resistance in Colorectal Cancer via Upregulation of ERCC1
por: Wei, Wei, et al.
Publicado: (2020)

Chidamide and Oxaliplatin Synergistically Inhibit Colorectal Cancer Growth by Regulating the RPS27A-MDM2-P53 Axis
por: Li, Zhaopeng, et al.
Publicado: (2023)

Association between Arachidonic Acid and the Risk of Schizophrenia: A Cross-National Study and Mendelian Randomization Analysis
por: Gao, Yan, et al.
Publicado: (2023)

Diaporine Potentiates the Anticancer Effects of Oxaliplatin and Doxorubicin on Liver Cancer Cells
por: Tian, Shiliu, et al.
Publicado: (2022)

Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer
por: Feliu, J, et al.
Publicado: (2004)

Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
por: Bang, Yeong Hak, et al.
Publicado: (2021)

Rechallenge of oxaliplatin-containing regimens in the third- or later-line therapy for patients with heavily treated metastatic colorectal cancer
por: Yang, Qiong, et al.
Publicado: (2018)

S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial
por: Kim, Seung Tae, et al.
Publicado: (2014)

Role of AMPK in Regulation of Oxaliplatin-Resistant Human Colorectal Cancer
por: Park, Sun Young, et al.
Publicado: (2022)

Role of oxaliplatin in the treatment of colorectal cancer
por: Comella, Pasquale, et al.
Publicado: (2009)

Oxaliplatin-Induced Neuropathy in Colorectal Cancer
por: Weickhardt, Andrew, et al.
Publicado: (2011)

The efficacy and safety of irinotecan ± bevacizumab compared with oxaliplatin ± bevacizumab for metastatic colorectal cancer: A meta-analysis
por: Dai, Jiali, et al.
Publicado: (2019)

Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy?
por: Osumi, Hiroki, et al.
Publicado: (2015)

Coexisting Molecular Determinants of Acquired Oxaliplatin Resistance in Human Colorectal and Ovarian Cancer Cell Lines
por: Noordhuis, Paul, et al.
Publicado: (2019)

Comparison of irinotecan and oxaliplatin as the first-line therapies for metastatic colorectal cancer: a meta-analysis
por: Kawai, Sadayuki, et al.
Publicado: (2021)

Oxaliplatin resistance in colorectal cancer enhances TRAIL sensitivity via death receptor 4 upregulation and lipid raft localization
por: Greenlee, Joshua D, et al.
Publicado: (2021)

Heterogeneous nuclear ribonucleoprotein L facilitates recruitment of 53BP1 and BRCA1 at the DNA break sites induced by oxaliplatin in colorectal cancer
por: Hu, Wenjun, et al.
Publicado: (2019)

TRIM29 Reverses Oxaliplatin Resistance of P53 Mutant Colon Cancer Cell
por: Lei, Guoqiong, et al.
Publicado: (2021)

Association of CYP24A1 gene polymorphism with colorectal cancer in the Jiamusi population
por: Chai, Lin, et al.
Publicado: (2021)

TRIM25 regulates oxaliplatin resistance in colorectal cancer by promoting EZH2 stability
por: Zhou, Sha, et al.
Publicado: (2021)

Oxaliplatin-Induced Senescence in Colorectal Cancer Cells Depends on p14(ARF)-Mediated Sustained p53 Activation
por: Tomicic, Maja T., et al.
Publicado: (2021)

Decytabine enhances cytotoxicity induced by oxaliplatin and 5-fluorouracil in the colorectal cancer cell line Colo-205
por: Flis, Sylwia, et al.
Publicado: (2009)

Oxaliplatin induces different cellular and molecular chemoresistance patterns in colorectal cancer cell lines of identical origins
por: Virag, Piroska, et al.
Publicado: (2013)

Clinical Analysis of Hypersensitivity Reactions to Oxaliplatin Among Colorectal Cancer Patients
por: Shen, Yuping, et al.
Publicado: (2018)

Gambogic acid reverses oxaliplatin resistance in colorectal cancer by increasing intracellular platinum levels
por: Wang, Qiang, et al.
Publicado: (2018)

Oxaliplatin resistance is enhanced by saracatinib via upregulation Wnt-ABCG1 signaling in hepatocellular carcinoma
por: Liao, Xia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8urrroi50dlj91e72fsc5mkub6